Clinical trial · Observational
Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs
Exploratory, Non-Interventional Study For Evaluating The Diagnostic, Prognostic And Response-Predictive Value Of A Multi Biomarker Approach In Metastatic GEP NETs
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut or pancreas. Using a recently developed methodology enabling the evaluation of 92 concomitant cancer biomarkers will provide an interesting approach to solve this question (Lundberg et al 2011).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Gastroenteropancreatic Neuroendocrine Tumors | Digestive System Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- GEP NETs
- description
- Patients with a suspected diagnosis of metastatic GEP NETs
- interventionNames
- Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
- label
- Healthy controls
- description
- Healthy controls matched by age and gender.
- interventionNames
- Other: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
Primary outcomes (1)
- measure
- Number of Participants With Progression Free Survival
- timeFrame
- Up to 60 months
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provision of written informed consent prior to any study related procedures. * Suspected of suffering from a metastatic midgut NET or Pancreatic non-functional NET (WHO grade 1 or 2, up to 10% Ki67). * Male or female aged 18 or older. Exclusion Criteria: * Previously treated for the NET disease with pharmaceutical treatment, Peptide Receptor Radionuclide Therapy (PRRT) or radiation therapy(surgery of primary tumour is accepted) * Has any mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude. * Suffering from a malignant disease or previously treated for a malignant disease within the last 6 months. * Suffering from a chronic inflammatory disease. * Suffering from a renal and/or liver disease.
References
Publications (1)
- DERIVEDKjellman M, Knigge U, Welin S, Thiis-Evensen E, Gronbaek H, Schalin-Jantti C, Sorbye H, Joergensen MT, Johanson V, Metso S, Waldum H, Soreide JA, Ebeling T, Lindberg F, Landerholm K, Wallin G, Salem F, Schneider MDP, Belusa R. A Plasma Protein Biomarker Strategy for Detection of Small Intestinal Neuroendocrine Tumors. Neuroendocrinology. 2021;111(9):840-849. doi: 10.1159/000510483. Epub 2020 Jul 28. PMID 32721955